NICE recommends Loncastuximab tesirine for DLBCL

The National Institute for Health and Care Excellence (NICE) has recommended loncastuximab tesirine as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma in adults after 2 or more systemic therapies. The treatment option is only available if they have previously been treated with polatuzumab vedotin, or if polatuzumab vedotin is not suitable.

Loncastuximab tesirine is a type of targeted treatment, known as an antibody-drug conjugate. Antibody–drug conjugates are monoclonal antibodies joined to a chemotherapy drug. The antibody is designed to stick to a protein on lymphoma cells and carry the chemotherapy drug directly to them

Loncastuximab tesirine is an additional treatment option when CAR-T cell therapy is not suitable.

Find out more about drug development, approval and funding, or visit Lymphoma TrialsLink for the latest on clinical trials for lymphoma.